Synosia strikes development deal with Novartis

Synosia Therapeutics is touting a deal to license the development rights--outside Japan--for Novartis' rufinamide as a therapy for anxiety disorder and bipolar mood disorders. No financial terms were disclosed, but Synosia heralded the pact as its second major agreement and a "major milestone" for the company. Synosia also gained the rights to an unnamed compound for diseases of the central nervous system.

"Rufinamide fits well with our innovative development approach," said Synosia CEO Dr. Ian Massey. "Rufinamide is a structurally novel compound with proven efficacy in epilepsy and an extensive safety database. It is rare for a start-up company to be offered this kind of opportunity and we look forward to exploring how best to expand its therapeutic potential in CNS through innovative, smart clinical trials."

- check out the release on the pact

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.